Startup Funding

Related Guides

Trending

The most popular articles on Startup Funding in the past day.

Convertible Notes vs. SAFE vs. Priced Rounds: Term Sheet Masterclass

5 min read Convertible Notes vs. SAFE vs. Priced Rounds: A Term Sheet Masterclass for Angel Investors   Early-stage investing is exciting, until the term sheet shows up. Convertible notes, SAFEs, valuation caps, discounts, pro-rata rights… the language alone can intimidate even experienced angels. Yet structure matters. The way a deal is papered can materially impact your ownership, downside protection, and long-term returns. In this masterclass-style breakdown, we’ll demystify the three most common early-stage investment structures and explain what every angel investor should understand before wiring funds.   The Three Core Structures (And Why They Exist) Before diving into mechanics, it’s important to understand why these structures exist in the first place. At the earliest stages, startups often don’t have enough traction to justify a firm valuation. Investors and founders need a way to move quickly without negotiating a full pricing exercise. That’s where convertible notes and SAFEs come in. Priced rounds, on the other hand, are more structured, more negotiated, and more formal. They’re typically used once a company has enough data to anchor valuation. Each structure reflects a tradeoff between speed, simplicity, investor protection, and clarity.   5 Key Takeaways Every Angel Should Know   1. Convertible Notes Are Debt—But They’re Designed to Convert Convertible notes are technically loans. They accrue interest and have a maturity date, but in practice, they’re designed to convert into equity during a future priced round. The investor protections come from two main levers: valuation caps and discounts. The cap limits the price at which your note converts, while the discount rewards you for investing early. As an investor, you want clarity on both, l, because your ownership ultimately depends on how these mechanics play out at conversion.   2. SAFEs Are Simpler—But Simplicity Can Shift Risk SAFEs (Simple Agreements for Future Equity) were designed to remove complexity. There’s no interest, no maturity date, and no repayment obligation. They convert into equity when a priced round occurs. While this simplicity makes deals move faster, it can also mean fewer structural protections for investors. There’s no ticking clock (like a maturity date), and some versions of SAFEs are less favorable in downside scenarios. Angels should pay close attention to the specific SAFE variant being used—post-money SAFEs, in particular, change dilution math significantly.   3. Valuation Caps and Discounts Determine Your Real Entry Price Caps and discounts aren’t just technical terms—they determine what percentage of the company you actually own. Valuation Cap: The maximum valuation at which your investment converts. Discount: A percentage reduction (e.g., 20%) on the next round’s share price. If a company raises at a $20M valuation but you invested on a $10M cap, your conversion happens at the lower number. That difference can double your effective ownership. Angels who ignore cap table math often discover too late that their “great deal” wasn’t so great. 4. Priced Rounds Offer Clarity—And Real Governance Rights In a priced equity round, you purchase shares at a fixed valuation. There’s no ambiguity about ownership—you know exactly what percentage you own from day one. Priced rounds also introduce more robust investor rights: Pro-rata participation Information rights Protective provisions Board representation (sometimes) For angels writing larger checks or building concentrated positions, priced rounds often provide stronger structural alignment and governance visibility. 5. Pro-Rata Rights Are a Silent Power Tool One of the most overlooked terms in early-stage investing is pro-rata rights—the ability to maintain your ownership percentage in future rounds. In breakout companies, your pro-rata rights can matter more than your initial entry terms. The ability to double down at later stages—when the company is de-risked—can dramatically improve portfolio returns. If you don’t secure pro-rata early, you may not get another chance. When Each Structure Makes Sense Convertible Notes are common when speed is critical and valuation is uncertain. SAFEs dominate in accelerator-driven and founder-friendly ecosystems. Priced Rounds emerge when companies have traction and institutional investors entering the cap table. As an angel, your goal isn’t to avoid any one structure—it’s to understand the leverage points inside each one. Because structure shapes outcome. The Bigger Picture: Structure Is Strategy Many angels focus primarily on valuation. But structure can be just as important. A low cap with no pro-rata can be limiting. A higher valuation with strong follow-on rights might be more valuable. A SAFE without clarity on dilution mechanics can surprise you later. Term sheets aren’t just legal documents. They are financial architecture. If you’re serious about building a disciplined angel portfolio, mastering these mechanics isn’t optional, it’s foundational.   Final Thought Investment structures don’t have to be confusing, but they do require intention. The angels who consistently generate strong returns aren’t just picking good founders. They understand the paper. If this breakdown was helpful, consider subscribing for deeper dives into startup investing mechanics, portfolio strategy, and capital deployment frameworks. And if you have questions about a specific term sheet you’re reviewing, drop a comment, we’ll tackle it in an upcoming edition.

Deal Flow Secrets: How to Access the Best Startups Before Other Investors

7 min read Deal Flow Secrets: How to Access the Best Startups Before Other Investors Every investor eventually learns the same hard truth: Returns don’t start with valuation. They start with access. By the time a startup shows up in your inbox through a generic pitch deck blast or a public platform, the real upside has often already been priced out. The most attractive opportunities—the ones that define top-quartile portfolios—are usually spoken for before they ever look like “deals.” This is where most new investors get stuck. They spend months building thesis decks, learning cap tables, and studying market trends—only to realize they’re looking at the same companies as everyone else, at the same time, with the same information. Deal flow is the bottleneck. And access is the edge. After facilitating over $900M in startup funding and working alongside a network of 25,000+ investors, I’ve seen exactly how the best investors consistently get earlier, cleaner, and higher-quality looks at companies. The good news: it’s not magic. It’s a system. Let’s break it down. The Deal Flow Myth Most Investors Believe Many investors assume that “great deal flow” means: Seeing more deals Being on more mailing lists Getting intros from more founders In reality, that usually leads to the opposite outcome: signal drowning in noise. Top investors don’t win by seeing everything.  They win by seeing the right companies earlier, filtered, and contextualized. The biggest mistake new investors make is optimizing for volume instead of curation. Where the Best Deals Actually Come From After reviewing thousands of deals across stages and sectors, high-quality startup opportunities tend to surface from only a handful of repeatable sources: 1. Founder-to-Founder Referrals Great founders know other great founders, often months before they start fundraising. These referrals happen quietly, long before a round is announced. 2. Second-Degree Investor Networks The best deals rarely come directly to you. They come through someone you trust, who trusts the founder. This is why isolated investors struggle to compete. 3. Structured Capital Introductions Companies raising intelligently don’t “spray and pray.” They target investors with relevant experience, aligned check sizes, and credible follow-on capacity. 4. Pattern Recognition Pipelines Experienced investors see recurring signals: market timing, customer pull, founder execution speed, and capital efficiency. Those patterns guide inbound filtering. Notice what’s missing from the list: Public pitch platforms Cold emails Demo day hype Those can occasionally surface winners—but they are not where consistent outperformance comes from. Why New Investors Struggle with Deal Flow Most new investors don’t lack intelligence or capital. They lack positioning. Here’s what’s usually working against them: No visible track record (yet) Limited founder trust Small or fragmented investor networks Inconsistent screening standards Overreliance on founder storytelling As a result, they often see deals after: Lead terms are set Valuations are stretched Allocation is tight At that point, even a great company becomes an average investment. The Real Advantage: Being Embedded, Not Invited The best investors aren’t “asking for access.” They are embedded in ecosystems where access is automatic. That’s the difference between: Chasing deals And having deals routed to you At TEN Capital, we’ve spent years building infrastructure around this idea—connecting founders, angels, family offices, VCs, and strategic investors into a shared deal intelligence network. Not a mailing list. Not a demo day. A curated, relationship-driven system. When you’re embedded: Founders approach you earlier Other investors share diligence proactively Signal improves before competition arrives How Serious Investors Upgrade Their Deal Flow If you want better deals, here’s what actually moves the needle: 1. Align With High-Signal Networks Strong networks act as multipliers. One good relationship can surface ten high-quality opportunities per year—each pre-vetted. 2. Specialize Before You Generalize Investors with clear theses attract relevant deals faster. “I invest in early-stage fintech” beats “I look at everything.” 3. Add Value Before You Invest Founders remember investors who help with hiring, customer intros, or strategic clarity—long before capital enters the conversation. 4. Use Structured Diligence, Not Gut Feel Early access is useless without disciplined evaluation. Pattern recognition beats charisma every time. Why Network Scale Matters More Than Ever Today’s startup market is more crowded—and more asymmetric—than ever. More founders More capital More noise In this environment, scale + curation matters. A network of 25,000+ investors doesn’t just mean reach—it means: Faster diligence triangulation Better pricing context Earlier visibility into competitive rounds Reduced information asymmetry This is why institutional investors dominate returns: they don’t operate alone. Individual investors who want institutional-level access need institutional-grade infrastructure. Deal Flow Is a System, Not a Lucky Break The biggest mindset shift successful investors make is realizing: Deal flow is engineered. It’s built through: Relationships Data Pattern recognition Trust Process Luck might get you one great deal. Systems get you great deals repeatedly. That’s the difference between dabbling and building a real investment practice. The Bottom Line If you’re consistently seeing: Over-market valuations Rushed allocation decisions Founder-driven hype cycles It’s not because you’re late to investing. It’s because you’re late to the network. The best startups don’t hide—but they do move quietly until the right capital shows up. Access changes everything. TEN Capital Due Diligence Prompt If you want to pressure-test a startup opportunity the way professional investors do, use the prompt below inside your diligence workflow or AI research tool: TEN Capital Due Diligence Prompt Analyze this startup as a professional early-stage investor. Assess the company across the following dimensions: Founder Quality & Execution Velocity – Background, prior wins/failures, decision speed, and evidence of founder-market fit. Market Reality – True addressable market vs. inflated TAM claims; urgency of the problem today. Product & Traction Signals – Customer pull, retention, usage patterns, and proof points beyond vanity metrics. Business Model Durability – Unit economics, pricing power, scalability, and path to profitability. Competitive Positioning – Direct and indirect competitors, switching costs, and defensibility. Capital Strategy – Use of funds, runway realism, future dilution risk, and follow-on attractiveness. Red Flags & Blind Spots – What would cause this investment to fail despite strong storytelling? Conclude with

Differentiation Isn’t Enough — In Deeptech Fundraising, the Real Goal Is Sounding Non-Replaceable

7 min read Differentiation Isn’t Enough — In Deeptech Fundraising, the Real Goal Is Sounding Non-Replaceable Every deeptech founder believes they are differentiated. They have patents. They have technical breakthroughs. They have scientific novelty. But here is the uncomfortable truth: Most differentiated deeptech companies still sound replaceable in a Series A–C pitch. The founder hears “unique technology.” The investor hears, “I’ve seen five versions of this already.” This disconnect isn’t about science. It’s about narrative physics. Deeptech founders compete on novelty, while investors evaluate replaceability risk, the risk that another team, corporate, academic lab, or stealth competitor could plausibly solve the same problem with a different approach. The difference between differentiation and non-replaceability is the difference between a pitch that earns polite interest and one that prompts a partner to fight for the deal internally. Let’s unpack how to shift your story from: “We’re differentiated,” to “No rational investor would pass on us — because no one else can credibly build what we’re building.” This is the art of sounding non-replaceable. The Wrong Goal: “Show Differentiation” Most deeptech founders think the goal is: Show unique IP Show better performance Show technical superiority Show a new architecture Show a novel materials approach This is differentiation, yes, but it’s not enough. Differentiation is merely a feature. Non-replaceability is a position. Investors increasingly expect technological differentiation, especially as AI, sensing, robotics, advanced materials, and climate hardtech reach commercialization maturity. Here is what Series A–C VCs fear far more than technical risk: Replaceability risk is the possibility that another team could solve the same problem with a similar probability of success. If you don’t neutralize replaceability risk, your entire story is fragile. Investors Are Pattern-Matching a Different Question Than You Think Founders think investors ask: “Is the technology good?” Investors actually ask: “Is this the team that will win the market?” And beneath that: “Can anyone else credibly do this?” Replaceability risk is a psychological evaluation, not a scientific one. Investors evaluate: Team rarity Domain advantage Execution asymmetry Insider access Market timing Customer lock-in potential Switching penalties: Architectural disadvantages in competitors A superior technology is meaningless if another group: Has deeper commercialization experience Has a better channel Has better supply chain agreements Has better OEM relationships Can raise more money faster Has a structurally advantaged team Replaceability is not a technical issue. It’s a narrative issue. Your story must shift from: Performance comparison to Positioning yourself as the only credible executor of this future. Framework #1 — The Non-Replaceability Index™ In deeptech, investors evaluate five dimensions of non-replaceability. A strong Series A–C narrative must hit all five: 1. Founder Rarity What combination of experience, insight, and exposure makes your team uniquely suited? Examples: DARPA/DoD-grade systems experience 15+ years in a niche domain Ex–Tesla or Ex–SpaceX manufacturing DNA Top 0.1% materials science or photonics expertise Narrative requirement: Show why no adjacent founder can replicate your intuition or insight velocity. 2. Architecture Lock-In Why is your solution architecture fundamentally harder to replicate? Examples: Proprietary data pipelines that improve faster with scale Control algorithms that get better with deployment Hardware–software co-design loops that create irreversible learning Narrative requirement: Show why alternatives will always be disadvantaged by physics, cost curves, or feedback dynamics. 3. Distribution Asymmetry What access or channel advantage do you have that competitors cannot match? Examples: OEM partnerships Industry incumbents backing your architecture Regulatory capture A primed early-adopter segment with an urgent need Narrative requirement: Show how you’ve secured “kingmaker” partnerships that create momentum no competitor can easily dislodge. 4. Switching Costs & Integration Depth Why does the first commercial user stick with you permanently? Examples: High integration depth Customized co-development loops Regulatory certification locked to your design Long-term supply agreements Narrative requirement: Show how your early integrations become long-term monopolies. 5. Ecosystem Gravity Why does the market start reorganizing around your solution? Examples: Standards adoption Tender specifications that match your design Industry-wide migration towards your architecture Supply chain consolidation favors your approach Narrative requirement: Show the gravitational pull of your solution, not just its novelty. Framework #2 — How to Construct a Non-Replaceable Deeptech Narrative Your story should follow a simple 4-step sequence: Step 1 — Define the Market Inevitability Start with the unstoppable trend. “The world is moving toward X whether anyone wants it or not.” Step 2 — Define the Constraint The core bottleneck is preventing inevitability. “This constraint has blocked progress for 20 years.” Step 3 — Reveal the Asymmetric Advantage Your unique unlock. “This team is the only team that can break the constraint because…” Step 4 — Demonstrate Irreversibility Why can’t the market go backward? “Once our architecture is deployed, the ecosystem standard shifts permanently.” This is how you sound like the only credible builder — not merely a differentiated one. Heuristic #1 — “If They Can Imagine Another Founder Doing It, You Lose.” Whenever you present: A milestone A technical advantage A partnership A customer win Ask: “Could an investor imagine another founder achieving this?” If yes, it doesn’t create non-replaceability. You must reframe around: Insight Access Irreversible commitments Asymmetric execution Architecture advantage Hard constraints that others can’t overcome Replaceability is a perception game. Heuristic #2 — “Show Not Just Why You Win, But Why Others Lose.” Deeptech founders are often too polite. They show their own strengths but avoid discussing competitive weaknesses. But investors need to hear why: Competing architectures hit scaling walls Incumbents face an incentive mismatch Alternatives fail economically Other approaches can’t meet integration requirements Competitors have timeline disadvantages You don’t need to attack competitors — you need to articulate the structural disadvantages of alternative paths. Heuristic #3 — “The Narrative Must Tie Technical Choices to Commercial Inevitability.” The best deeptech founders explain: Why is their architecture commercially privileged Why their design choices accelerate adoption Why alternatives become unscalable at commercial volumes Why customers gain more from switching earlier Investors love inevitability. Make your narrative about inevitability, not innovation. Pattern Recognition: What Non-Replaceable Deeptech Companies Have in Common Looking across robotics, autonomy, advanced sensors, energy

How Artificial Intelligence Is Transforming Venture Capital and Startup Investing

7 min read How Artificial Intelligence Is Transforming Venture Capital and Startup Investing For decades, venture capital has been driven by human intuition. Investors relied on pattern recognition, personal networks, and experience to identify promising startups. A compelling founder, a strong market narrative, or a new technology trend often shaped investment decisions. While these instincts remain valuable, the startup ecosystem has grown far more complex. Today, millions of data points are generated across the technology landscape, from developer activity and product usage to hiring trends and customer sentiment. Artificial intelligence is now helping investors analyze this growing universe of information. Rather than replacing venture capitalists, AI is augmenting the way they discover opportunities, evaluate companies, and manage their portfolios. As technology continues to evolve, it is reshaping how venture capital operates. Expanding the Startup Discovery Process Traditionally, venture capital deal flow came from a relatively small set of sources: founder referrals, accelerator programs, personal networks, and introductions from other investors. While these channels remain important, they can also limit visibility. Many promising startups operate outside established venture networks, particularly in emerging ecosystems or specialized industries. AI-powered sourcing tools are changing this dynamic by scanning vast datasets to identify early signals of promising companies. These systems can analyze factors such as hiring activity, open-source software contributions, patent filings, website growth, and developer engagement. By identifying patterns that suggest early momentum, AI allows investors to discover startups long before they appear on traditional venture radars. The result is a broader and more diverse pipeline of potential investments. Data-Driven Market Insights Understanding which markets will grow, and when, is one of the most difficult challenges in venture investing. Historically, investors relied heavily on industry reports, expert opinions, and the founder’s vision to evaluate market opportunities. Artificial intelligence now provides a new layer of insight by analyzing large-scale market data. Machine learning models can process information across multiple industries simultaneously, identifying emerging patterns that may signal future growth. These systems can track trends in technology adoption, funding activity, regulatory changes, and consumer behavior. By identifying correlations across thousands of data points, AI helps investors recognize market shifts earlier than traditional research methods. While it does not eliminate uncertainty, this approach improves investors’ ability to anticipate where innovation may accelerate. Faster and More Efficient Due Diligence Evaluating startups requires significant research. Investors must analyze market size, competition, financial projections, and product differentiation before committing capital. AI tools are helping streamline this process. Natural language processing systems can quickly analyze large volumes of text, including pitch decks, research reports, customer reviews, and news coverage. These tools can summarize key insights, highlight potential risks, and compare startups across industry benchmarks. By automating information gathering and analysis, AI allows venture teams to evaluate more opportunities while focusing their time on strategic judgment rather than manual research. Supporting Investment Decisions with Predictive Models Some venture firms are experimenting with machine learning models trained on historical startup outcomes. These models analyze variables such as founder experience, team composition, capital efficiency, and early traction signals. The goal is not to predict winners with certainty—startup success is too complex for that. Instead, predictive models provide probability-based insights that can support investment discussions. They help investors compare opportunities more systematically and identify potential risks that may not be immediately visible. When used properly, these tools serve as decision support systems rather than replacements for human judgment. Improving Portfolio Support Artificial intelligence is also influencing how venture firms support the companies they invest in. AI-driven platforms can monitor portfolio performance by analyzing signals such as customer growth, hiring trends, product usage, and market competition. These insights allow investors to identify potential challenges earlier and provide more targeted strategic guidance. Instead of reacting only during board meetings or funding rounds, investors can maintain a more continuous understanding of how their companies are performing within the broader market. The Growing Importance of Data Infrastructure As AI becomes more integrated into venture capital, the value of proprietary data is increasing. Many leading firms are building internal platforms that track deal flow, diligence insights, founder interactions, and portfolio performance. Over time, these datasets become powerful assets that improve the accuracy of AI-driven insights. Firms with stronger data infrastructure will be better positioned to identify patterns across markets, founders, and business models. In venture capital, information is increasingly becoming a competitive advantage. The Challenges of AI in Venture Capital Despite its potential, AI introduces several challenges for investors. One of the biggest risks is overreliance on algorithms. Many of the most successful startups initially looked unconventional and would not have matched historical patterns. If investors depend too heavily on predictive models, they may miss disruptive companies that do not fit existing data trends. There are also concerns around bias. AI models learn from historical data, which may reflect past inequalities in venture funding. Without careful design and oversight, algorithms could unintentionally reinforce those biases. Finally, building AI capabilities requires significant technical expertise and infrastructure. Not every venture firm has the resources to develop sophisticated data platforms. The Future of AI in Venture Investing Artificial intelligence is unlikely to replace venture investors, but it is changing how they operate. The most successful firms will likely adopt a hybrid approach that combines human insight with machine-assisted analysis. AI can help surface opportunities, analyze complex data, and streamline research, while experienced investors interpret those signals and make final decisions. As the startup ecosystem continues to grow and generate more data, AI will play an increasingly important role in helping investors navigate it. For venture capital firms, the question is no longer whether artificial intelligence will influence investing. It is how effectively they can integrate it into their decision-making processes. If your firm is exploring how emerging technologies are reshaping startup ecosystems and investment strategies, staying informed about AI’s role in venture capital will be critical. The investors who successfully combine data-driven insights with human judgment will be best positioned to identify the next generation of transformative companies.

The Art and Science of Screening a Deal

7 min read The Art and Science of Screening a Deal: How investors can use first-pass filters, scoring matrices, and data-driven checklists to identify high-potential startups faster.   Early-stage investing isn’t about finding certainty—it’s about filtering signal from noise efficiently. With inbound deal flow at all-time highs, the real bottleneck for angels, family offices, and funds is no longer access to opportunities, but decision velocity with discipline. The best investors don’t evaluate every deck equally; they apply structured screening systems that surface the few opportunities worth deeper diligence. Screening is both an art and a science. The science lives in repeatable filters, scoring models, and objective criteria. The art lies in judgment—knowing when a company breaks the rules for the right reasons. Below is a practical, investor-ready framework for building a strong first-pass screening process that saves time, reduces bias, and improves outcomes. 1. First-Pass Filters: Decide What Doesn’t Belong Before scoring, eliminate misalignment early. First-pass filters should answer one question quickly: Is this deal even worth time? a. Stage & Check Size Fit Most deals fail here. Clarify upfront: Revenue or traction stage (pre-seed, seed, growth Typical check size and ownership targets Ability to follow on If the company doesn’t fit your mandate, pass fast and clean. b. Sector & Thesis Alignment Avoid “interesting but off-strategy” traps. Screen for: Core sectors, you understand Problems you believe matter Markets where you have pattern recognition Thesis discipline compounds over time. c. Geography & Jurisdiction Regulatory and operational friction varies widely. Filter based on: Geographic focus Regulatory exposure ,you’re comfortable underwriting Ability to support the company post-investment First-pass filters protect focus and bandwidth. 2. Scoring Matrices: Bring Structure to Subjectivity Once a deal clears initial filters, apply a simple scoring matrix to compare opportunities consistently. a. Core Dimensions to Score Limit scores to what actually predicts outcomes: Founder–market fit Traction quality Market clarity Capital efficiency Execution readiness Avoid over-scoring vision or TAM in isolation. b. Use Relative, Not Absolute Scores Scores matter most across your own deal set, not in isolation. Ask: Is this stronger or weaker than other deals this month? Where does it rank in the top 10–20%? This sharpens prioritization. c. Weight What You Value Not all factors are equal. For example: Early-stage angels may weigh founders higher Family offices may weigh downside protection and governance Funds may weigh scalability and exit paths Scoring systems should reflect your capital’s objectives. 3. Data-Driven Checklists: Reduce Bias, Increase Speed Checklists ensure you ask the same questions every time—especially under time pressure. a. Founder & Team Checklist Look for: Clear role ownership Evidence of execution together Coachability and learning velocity Gaps the team acknowledges (not denies) Red flag: defensiveness over curiosity. b. Traction & Market Checklist Validate: Who is paying (or piloting) and why Repeatability across similar customers Clear ICP definition Sales cycle realism Green flag: founders can explain why deals don’t close. c. Financial & Capital Checklist Screen for: Burn vs. milestones achieved Clean cap table Use-of-funds clarity Runway awareness Early financial hygiene predicts later governance quality. 4. Pattern Recognition: Compare to Known Outcomes Great screeners constantly ask: What does this remind me of? a. Positive Patterns Look for signals you’ve seen before: Second-time founders correcting past mistakes Early customers behaving like reference buyers Clear narrowing of focus over time b. Risk Patterns Watch for recurring failure modes: “Too many use cases.” Revenue driven by one non-repeatable customer Fundraising as the strategy Pattern recognition improves with documentation—write down why you passed. 5. Decision Buckets: Triage, Don’t Debate Every screened deal should land in one of three buckets: Advance → deeper diligence Monitor → stay close, request updates Pass → clear, respectful decline The goal is not perfection; it’s momentum with clarity. Strong investors don’t win by seeing more deals; they win by screening better. First-pass filters protect focus. Scoring matrices create consistency. Checklists reduce bias. Together, they allow investors to move faster without sacrificing rigor. Screening is not about saying “no” more often; it’s about saying “yes” with conviction when it matters. The best deals don’t always look perfect at first glance, but the best investors know exactly why they’re leaning in. Want to professionalize your deal screening process? Join our investor community to access proven screening templates, scoring matrices, and diligence frameworks designed to help you identify high-potential startups faster—before the rest of the market catches on.

How to Diligence a Deal Beyond the Deck

10 min read How to Diligence a Deal Beyond the Deck A practical framework for investors to go deeper than the pitch—focusing on risk domains, capital discipline, and founder transparency. Pitch decks are designed to persuade, not to fully inform. They highlight upside, compress complexity, and often gloss over risk. For investors, relying on the deck alone is one of the fastest ways to misprice risk and overestimate execution. Whether you’re an angel investor, family office, strategic, or venture fund, diligence on a deal beyond the deck requires a structured, skeptical, and evidence-driven approach. The goal isn’t to kill deals to build conviction by understanding where things can break and whether the team has the discipline to navigate those risks. Below is a practical framework to go deeper than the pitch and evaluate a company across its true risk domains. 1. Business Model Clarity & Unit Economics   a. How the Company Actually Makes Money Start by stress-testing the revenue model—not the TAM slide. Ask: Is revenue transactional, recurring, usage-based, or contract-driven? Who is the buyer vs. the end user? What triggers revenue recognition? Break down cost drivers: COGS or service delivery costs Sales commissions and customer success Infrastructure, tooling, or third-party dependencies Look for: Clear margin expansion logic Evidence that costs decline with scale, not just assumptions If unit economics don’t work at a small scale, they rarely work later. b. LTV, CAC, and Payback Reality Founders often present optimistic LTV/CAC ratios. Your job is to pressure-test them. Validate: CAC by channel (not blended averages) Sales cycle length by customer segment Retention, expansion, and churn assumptions Ask: How long does it take to recover CAC on a cash basis? What happens to CAC as the company scales? Are early customers representative—or exceptions? c. Pricing Power & Market Sensitivity Understand whether pricing is: Cost-plus Value-based Competitive or commoditized Test: What happens if prices drop 20%? Can customers easily switch? Is pricing driven by ROI, urgency, or convenience? Real businesses survive pricing pressure. Fragile ones don’t. 2. Risk Domains: Where the Business Can Break Great diligence maps risk before upside. Key risk domains to assess: Market risk (is the problem real and urgent?) Product risk (does it work as claimed?) Execution risk (can the team deliver?) Financial risk (capital sufficiency and burn discipline) Regulatory or compliance risk (if applicable) Dependency risk (customers, vendors, platforms) Ask founders directly: “What are the top three things that could kill this company?” How they answer matters as much as what they say. 3. Product Reality vs. Product Narrative   a. Product-Market Fit Evidence Look for proof—not promises. Validate through: Customer usage data Retention and engagement metrics Pilot-to-paid conversion rates Reference calls with real users Red flags: Heavy roadmap focus with light customer evidence Features driving excitement but not retention “Design partners” that never convert b. Roadmap Discipline A strong roadmap is prioritized, resourced, and sequenced. Ask: What gets built next—and why? What’s customer-driven vs. founder-driven? What milestones unlock revenue or margin? Avoid teams chasing breadth before depth. 4. Go-to-Market Execution   a. Sales Motion Fit Evaluate whether the GTM motion aligns with the product and the buyer. Assess: Self-serve vs. sales-led vs. enterprise Founder-led sales dependency Channel vs. direct strategy Red flags: Long enterprise cycles without a capital runway Complex sales motions with junior teams No clear ICP definition b. Pipeline Quality Inspect pipeline health—not just top-line numbers. Look for: Stage conversion rates Deal slippage patterns Customer concentration risk One “logo” does not equal traction. 5. Founder Transparency & Integrity This is where diligence moves from analytical to judgment-based. Strong founders: Share bad news early Acknowledge weaknesses Provide clean, consistent data Don’t over-defend assumptions Watch for: Shifting answers across meetings Overly polished responses to hard questions Resistance to data requests Trust is built through consistency under pressure. 6. Team & Execution Capacity   a. Role Coverage Evaluate whether critical functions are owned: Product Sales Operations Finance Early-stage teams don’t need depth everywhere—but they need awareness of gaps. b. Execution Track Record Ask: What milestones were hit late—and why? Where has the team over- or under-estimated? How do they course-correct? Past execution is the best predictor of future execution. 7. Financial Discipline & Capital Strategy   a. Burn vs. Learning Healthy burn drives learning and de-risking—not just growth optics. Assess: Monthly burn vs. milestone progress Headcount growth vs. productivity Spend aligned to key risks   b. Capital Plan Reality Understand: How long does the current capital last What milestones justify the next raise Downside survival scenarios Ask: “If fundraising takes 6 months longer than expected, what happens?” 8. Cap Table & Incentive Alignment Review: Ownership distribution SAFEs, notes, and preference stacks Employee option pool health Red flags: Overcrowded early cap tables Misaligned investor rights Founder dilution that kills motivation 9. Market Context & Competitive Positioning Map: Direct competitors Indirect substitutes Incumbent responses Assess: Switching costs Differentiation durability Speed of competitive response Winning often depends on timing, not just product quality. 10. Exit Logic & Investor Fit   a. Plausible Exit Paths Ask: Who buys companies like this? At what scale? On what metrics? Hope is not a strategy, exits follow patterns. b. Alignment Check Finally, assess: Time horizon fit Risk tolerance alignment Strategic vs. financial expectations A good deal for someone else can be a bad deal for you. Final Thoughts Diligencing a deal beyond the deck is about discipline, curiosity, and humility. It means resisting the story long enough to examine the structure underneath—and deciding whether the risks are known, manageable, and worth taking. By applying a structured framework, grounded in unit economics, risk domains, founder transparency, and capital discipline, you move from guessing to conviction. The best investors don’t avoid risk. They understand it better than anyone else in the room.   Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

How to Diligence a Cleantech Firm

7 min read How to Diligence a Cleantech Firm Diligence for a cleantech firm requires a different lens than for traditional software, CPG, or marketplace investing. Whether you’re an angel investor, family office, strategic, or VC, evaluating a cleantech business means examining technology readiness, regulatory compliance, unit economics, carbon impact, capital intensity, and infrastructure dependencies. Here’s a structured, risk-aware playbook to diligence a cleantech company with confidence. 1. Understand the Business Model & Unit Economics   a. Revenue Model & Cost Structure Determine whether the company generates revenue through hardware sales, SaaS layers, project development, installation contracts, or long-term service agreements (e.g., O&M or energy-as-a-service). Break down COGS: components, engineering labor, installation, freight, commissioning, and warranty obligations. Ask how margins improve with volume: Are hardware components commoditized or proprietary? Do economies of scale significantly reduce manufacturing costs? Are service contracts profitable over their lifecycle? b. Lifetime Value (LTV) & Customer Acquisition Costs (CAC) For enterprise or municipal customers: What is the expected contract term? How often do customers expand deployments? What is the churn for service agreements? For residential solutions (e.g., solar installers, battery providers): Evaluate gross profit per project. Compare customer lifetime profit to CAC and installation labor costs. c. Pricing Strategy How price-sensitive is the market? Does the company compete on cost savings, performance, or sustainability ROI? How do market incentives (tax credits, grants, utility rebates) affect pricing? Ensure the pricing model remains viable even if subsidies decrease or competition intensifies. 2. Technology Readiness & Scalability Risks   a. Technology Validation (TRL Levels) Assess technology readiness: Has it been lab-validated, pilot-tested, or commercially deployed? Request: Independent validation reports Performance data Warranty or reliability metrics Identify any unproven assumptions that could hinder commercialization. b. Manufacturing & Supply Chain Where and how is the product manufactured? In-house, outsourced, or contract manufacturing? Are critical components single-source (e.g., rare earth metals, lithium cells)? Evaluate supply-chain resiliency: Lead times Supplier diversification Exposure to geopolitical risk c. Scalability Constraints Does scaling require: Large capex investment? Specialized labor? Utility interconnection approval? Local permitting or environmental assessments? Assess whether physical constraints—not just demand—could limit growth. 3. Market & Go-to-Market Strategy   a. Target Market & Adoption Curve Who are the customers—utilities, industrials, municipalities, real estate developers, corporates, or consumers? Analyze: Market size Market fragmentation Regulatory tailwinds (e.g., IRA incentives, net metering policy) Determine if the market is ready for the solution or if customer education will slow sales cycles. b. Sales Model & Distribution Is the company using direct sales, channel partners, installers, EPCs, or distributors? For enterprise or government sales: Review sales cycle length Contract structure RFP dependency Proof of traction with anchor customers c. Customer Proof & Brand Positioning Evaluate customer testimonials, commercial pilots, and measurable outcomes (e.g., kWh reduction, CO₂ saved, O&M savings). Assess whether the company’s differentiation—performance, sustainability, cost savings, or reliability—is real and defensible. 4. Regulatory, Policy & Compliance Considerations   a. Certifications & Safety Request certification documents such as: UL, CE, ISO standards Grid interconnection compliance (e.g., IEEE standards) Environmental or emissions certifications Check whether the product has undergone third-party testing. b. Policy Dependencies Many cleantech firms depend on incentives. Understand: How the business performs with and without subsidies Risks from policy changes Exposure to tariffs, import duties, or trade restrictions c. Permitting, Interconnection & Local Regulations For grid-dependent products: Interconnection timelines Utility approval processes Permitting risks For environmental tech: EPA, state-level environmental regulation Potential liabilities (e.g., waste handling, emissions compliance) 5. Product & Innovation Pipeline   a. Product-Market Fit Review pilot results, customer feedback, reliability metrics, uptime rates, and warranty claims. Evaluate whether early adopters are becoming long-term customers, and whether the product delivers measurable ROI. b. R&D Roadmap Ask for: Pipeline of next-gen technology Development timelines Budget allocation between R&D and commercialization Intellectual property strategy (patents, trade secrets) Request evidence of technical milestones, not just conceptual roadmaps. c. Competitive Moats Assess whether the company’s innovation is defensible through: Patents Proprietary materials or algorithms Exclusive supply agreements Data advantages High switching costs 6. Team & Operational Execution   a. Founding Team & Technical Expertise Do founders have expertise in energy, engineering, sustainability, hardware, or manufacturing? Have they brought physical technology to market before? b. Organizational Strength Examine structure across engineering, operations, sales, installation, and regulatory functions. Evaluate whether the company has: Solid program/project management Scalable operational processes Strong supply chain and field operations teams c. Execution Metrics Request KPIs such as: Deployment timelines Installation costs Uptime and reliability metrics Warranty claim rates On-time delivery and backlog status Look for signs of operational discipline like documented SOPs and audited processes. 7. Financials & Capital Structure   a. Historical Financials Request: 2–3 years of financial statements Cash flow breakdown (critical for capex-heavy firms) Gross margin trends Equipment and installation cost data Assess whether the company’s growth justifies its burn rate. b. Financial Model & Scenarios Review projections with a focus on: Unit economics under scale Sensitivity to commodity prices Capex requirements for growth Working capital needs (especially for hardware) Installation labor availability Model downside cases: What if incentives drop, cost of materials rises, or deployment slows? c. Cap Table & Funding Requirements Request a detailed cap table including SAFEs, notes, and options. Understand: Existing investor rights Liquidity preferences Future capital needs and dilution risk Dependency on project financing or credit facilities 8. Customer Validation & Market Risk   a. Customer References Speak with customers in pilot or commercial deployments. Ask: Did the technology meet expectations? Was the installation smooth? Did it generate real cost or carbon savings? Would they expand usage? b. Competitive Landscape Map direct and indirect competitors: Incumbents Emerging cleantech startups Cross-category substitutes (e.g., batteries vs. thermal storage) Assess defensibility and switching costs. c. Infrastructure & Channel Risk Evaluate dependencies such as: Utility approval cycles Installation labor availability Supply chain bottlenecks Dependence on one large customer or geographic region 9. ESG, Sustainability & Risk Management   a. Environmental Impact Request lifecycle analyses or carbon footprint data. Verify claims around emissions reduction, recyclability, and energy savings. b. Resilience &

How to Diligence a CPG Firm

7 min read How to Diligence a CPG Firm Diligencing a consumer packaged goods (CPG) business has nuances that set it apart from pure software or marketplace investing. Whether you’re an angel investor, family office, or VC, evaluating a CPG company means diving into supply chain dynamics, product economics, brand strength, and more. Here’s a structured, risk-aware playbook to help you evaluate a CPG firm like a pro. 1. Understand the Business Model & Unit Economics Gross Margins and Cost Structure Ask for a breakdown of the cost of goods sold (COGS): raw materials, packaging, labor, and overhead. Determine how variable costs scale: Does margin improve with volume, or are there fixed costs that drag at low volumes? Verify whether the company’s pricing is sustainable in different sales channels (direct-to-consumer vs. retail). Lifetime Value (LTV) vs. Customer Acquisition Cost (CAC) If the company sells direct to consumers, evaluate repeat purchase behavior: what is the retention rate over 6- and 12-month cohorts? For wholesale distribution, calculate the per-customer margin and reorder frequency. Model LTV in each channel and compare it against CAC across those same channels. Pricing Strategy and Sensitivity How elastic is demand for their products? If costs rise or discounts shrink, how will that impact volume? What is their value narrative — are they competing on premium quality, sustainability, or price? That will shape pricing power. 2. Supply Chain & Manufacturing Risks Sourcing and Raw Materials Who are their suppliers, and how diversified is the supply base? Are there single-source risks? (e.g., only one supplier for a key ingredient.) What is the lead time for critical raw materials, and how volatile are their costs? Manufacturing Capacity & Scalability Where is the product manufactured? In-house, co-packer, or a network of partners? If they use co-packers, do they have contracts in place, and is there slack capacity for scaling? Are there quality control systems? Ask for defect rates, returns, or consumer complaints. Inventory Management What is their inventory turnover? High inventory on hand could indicate demand forecasting risk. How do they manage shelf life, especially for perishable or seasonal products? What’s the working capital tied up in inventory — is it a cash drag? 3. Go-to-Market Strategy Distribution Channels Where do they sell: DTC (direct-to-consumer), brick & mortar retail, grocery chains, or specialty stores? For retail distribution: what’s their push strategy? Do they have favorable slotting terms? What are their trade spend and promotional allowances? For DTC: analyze their customer acquisition channels (paid ads, organic, SEO, email), conversion rates, and cost per acquisition. Brand Strength & Positioning What is the company’s brand story, and how does it resonate with its target customer? Do they have customer testimonials or social proof (e.g., reviews or word of mouth)? How do they differentiate (taste, packaging, sustainability, health angle)? Is this differentiation defensible, or is it easily copied Marketing Efficiency What percentage of revenue is being reinvested into marketing? How efficient are their sales funnels? (e.g., Email open/click rates, ad ROAS, conversion from trial/sample to repeat purchase) Are there community or viral growth vectors (referral programs, user-generated content, influencers) 4. Regulatory and Compliance Considerations Food Safety & Quality Does the CPG company comply with relevant regulatory bodies (FDA in the U.S., local food safety authorities elsewhere) Request documentation such as HACCP plans, food safety audits, or third-party quality certifications (e.g., SQF or BRC). How do they handle product recalls, and what is their track record? Packaging & Labeling Are labels compliant with nutrition, ingredient, and allergen disclosure regulations? Does the firm use any sustainable or recyclable packaging? If yes, how does that impact COGS and supply chain risk? Environmental, Social, Governance (ESG) If ESG is part of their value prop (eco-friendly, local sourcing), verify their claims with evidence, such as supplier audits, lifecycle assessments, carbon impact assessments, etc. Are there sustainability-related liabilities (e.g., packaging waste, carbon offset obligations)? 5. Product & Innovation Evaluation Product-Market Fit Conduct a sensory evaluation: sample the product (if possible) or collect feedback from early customers. Analyze repeat purchase rates, product lifecycle (i.e., are customers buying again, or is it a “try once” product?). How broad is their SKU (stock-keeping unit) mix? Do they plan to expand into new SKUs or adjacent categories? Innovation Pipeline Do they have a roadmap for new flavors, size formats, or product lines? How much of their R&D or product development budget is allocated to innovation vs. core SKUs? Have they tested new products in pilot markets? What were the results? 6. Team & Operational Execution Founders & Leadership What is the founding team’s background? Do they have experience in consumer goods, manufacturing, or retail? Have they scaled a physical product business before, or is this their first CPG venture? Meet the team responsible for operations, supply chain, and quality — are they capable of handling scale? Organizational Structure How is the organization structured across procurement, manufacturing, sales, and marketing? Do they have robust systems for demand forecasting, production planning, and logistics? What is their talent strategy for hiring and retaining people in key roles? Execution Metrics Ask for KPIs such as yield rates, batch failure rates, on-time delivery, inventory shrinkage, and return rates. How quickly have they scaled since launch — both in production volume and sales? What evidence is there of operational discipline (e.g., documented SOPs, contracts with co-packers, audits)? 7. Financial & Capital Structure Historical Financials Request P&L statements, balance sheets, and cash flow for at least the past 2–3 years. Compare their burn rate vs. growth: are they reinvesting heavily, or burning cash without traction? Understand working capital needs: how much cash is tied up in inventory or accounts receivable (especially for retail customers)? Projections & Scenario Modeling Review their financial model: are their assumptions realistic around growth, margins, and cash needs? Run downside and base-case scenarios: what happens if growth slows, COGS rise, or customer acquisition costs increase? How much capital will they need to scale, and what is their runway? Cap Table & Funding History Ask for a full

How to Diligence a Therapeutic Startup

7 min reading How to Diligence a Therapeutic Startup “In therapeutic investing, the science must be right, but the strategy must be smarter.” Diligencing a therapeutic startup is unlike any other form of early-stage investing. It requires balancing scientific rigor with business realism. From molecule to market, investors must evaluate not just whether the science works, but also whether the pathway to revenue and, eventually, to exit is both capital-efficient and strategically defensible. In this article, we distill insights from Startup Funding Espresso episodes on diligence, biotech assessment, and founder fit to create a structured playbook for investors, founders, and diligence teams navigating therapeutic innovation. The Purpose of Diligence Therapeutic startups operate at the intersection of science, regulation, and capital markets. The goal of diligence is to validate alignment across three domains: Technical feasibility — Does the underlying science or technology platform hold up under scrutiny? Regulatory viability — Is there a clear pathway through the FDA, EMA, or equivalent agencies? Commercial potential — Is the market large enough, accessible enough, and ready enough to support sustained adoption? The episode “Setting up Due Diligence” underscores that diligence is not a checklist but a risk-reduction process. Each layer, technical, market, financial, and team, reveals not only what’s known but also where uncertainty resides. Key Pillars of Therapeutic Diligence Across episodes like “What Investors Look for in a Biotech Startup”, “Core Skills for Biotech Drug Development”, and “Best Practices for Therapeutic Startup Fundraising,” five diligence pillars consistently emerge: a. Scientific Validity Evaluate the mechanism of action and supporting pre-clinical data. Look for peer-reviewed validation or collaborations with credible institutions. Avoid overreliance on early, non-replicated studies. b. Regulatory Readiness Determine if the company understands its regulatory classification (drug, biologic, device, or combination product). The episode “Key Documents for Your Due Diligence Box” reminds investors to confirm the presence of pre-IND or pre-submission feedback and a mapped timeline to key milestones (IND, Phase I/II/III, etc.). c. Intellectual Property Strong IP defines competitive durability. Diligence teams should verify patent ownership, freedom-to-operate analyses, and upcoming expirations. The episode “Red Flags in Due Diligence” lists weak patent coverage and licensing ambiguity as common deal-killers. d. Market and Reimbursement The episode “How to Diligence the Market” highlights the importance of mapping addressable markets, reimbursement codes, and pricing elasticity early. In therapeutics, the buyer is often not the user; understanding payer dynamics is as critical as clinical efficacy. e. Team and Execution From “How to Diligence the Team” and “How Much Diligence to Run on a Founder,” we learn that successful therapeutic founders combine scientific depth with regulatory and commercial literacy. Look for balanced teams, scientific founders complemented by business operators and regulatory veterans. Evaluating the Science: From Discovery to Translation Scientific diligence is both art and analytics. The episodes “Technical Due Diligence” and “Performing Due Diligence Like a VC” emphasize reviewing: Preclinical data integrity (sample sizes, control design, statistical significance). Translational relevance (animal model to human trial correlation). Scalability of the therapeutic platform (manufacturing, formulation, delivery). Replicability and documentation quality. The diligence process should involve external subject-matter experts who can assess biological plausibility and experimental design. Investors often underestimate how manufacturing complexity and stability testing can become multi-million-dollar bottlenecks post-Series A. Regulatory Diligence: Navigating the FDA Maze Episodes like “Due Diligence: The Thorough Approach” and “Signing NDAs in Due Diligence” note that regulatory diligence is not just about confidentiality; it’s about clarity. Investors should verify: Has the company engaged with the FDA through pre-IND or Q-submission meetings? Does the clinical plan align with regulatory precedent? Are timelines and budgets realistic given the required studies? For devices and diagnostics, the 510(k), De Novo, and PMA pathways drastically change time-to-market and capital requirements. For drugs, investors should validate the clinical endpoints that regulators will recognize and the CMC (Chemistry, Manufacturing & Controls) readiness. Market Validation and Adoption Risk The episodes “How to Perform Marketing Due Diligence” and “The Role of Social Media in Due Diligence” remind us that even brilliant therapies fail if they can’t cross the commercial chasm. Critical diligence questions include: Who pays for this therapy—patients, insurers, or hospitals? What’s the comparative cost versus the current standard of care? How do KOLs (Key Opinion Leaders) view the therapeutic value? Savvy investors go beyond market sizing they look for evidence of early traction, like investigator interest, LOIs from clinics, or grants validating unmet needs. Financial and Risk Diligence In “Financials, Team and Domain Diligence” and “Going Through Due Diligence,” Hall T. Martin highlights the need to align scientific milestones with capital tranches. Key insights include: Link fundraising to de-risking events (e.g., IND submission, Phase I completion). Assess capital efficiency: how much per data point? Model downside scenarios: what happens if the lead candidate fails? Therapeutic startups should demonstrate clear cash-to-value conversion, showing how each dollar accelerates the next stage of validation. Qualitative and Quantitative Diligence From “The Quantitative and Qualitative Side of Due Diligence,” effective investors integrate metrics and intuition. Quantitatively, they evaluate market size, runway, and clinical timelines. Qualitatively, they examine founder motivation, transparency, and resilience. The best diligence blends data with discernment; a founder’s honesty in disclosing failed experiments often signals stronger integrity than perfect slides. Common Red Flags Episodes like “Red Flags in Due Diligence” and “What Isn’t Being Said in Due Diligence” reveal recurring warning signs: Overstated preclinical results or missing negative data. Lack of clarity on IP ownership or licensing. Unrealistic regulatory timelines. Founders are resistant to third-party validation. Weak capitalization structure or unrecorded convertible debt. Any one of these can indicate a lack of maturity in governance or readiness for institutional investment. Building the Due Diligence Box The “Key Documents for Your Due Diligence Box” episode lists must-have files: Executive summary and pitch deck Scientific white papers IP portfolio summary Regulatory correspondence Financial model and cap table Team bios and advisory board profiles For therapeutics, include clinical protocol summaries and manufacturing validation reports. Organizing these early signals professionalism and preparedness. Performing Diligence Like a VC In “Performing Due Diligence Like a VC,” the guidance

Site Map

Scroll to Top